{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:28:13Z","timestamp":1761128893349},"reference-count":88,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.2515\/therapie\/2011002","type":"journal-article","created":{"date-parts":[[2011,4,7]],"date-time":"2011-04-07T04:58:14Z","timestamp":1302152294000},"page":"63-72","source":"Crossref","is-referenced-by-count":2,"title":["Suivi th\u00e9rapeutique pharmacologique du m\u00e9thotrexate \u00e0 faible dose dans les maladies inflammatoires"],"prefix":"10.1016","volume":"66","author":[{"given":"Marie-Cl\u00e9mence","family":"Verdier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Tribut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Bodeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doroth\u00e9e","family":"Rihouey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dani\u00e8le","family":"Bentu\u00e9-Ferrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.2515\/therapie\/2011002_bb0005","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.semarthrit.2003.12.003","article-title":"The use of methotrexate in rheumatoid arthritis","volume":"34","author":"Borchers","year":"2004","journal-title":"Semin Arthritis Rheum"},{"key":"10.2515\/therapie\/2011002_bb0010","first-page":"473","article-title":"Methotrexate in rheumatoid arthritis","volume":"58","author":"Swierkot","year":"2006","journal-title":"Pharmacol Rep"},{"key":"10.2515\/therapie\/2011002_bb0015","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/BOR.0b013e328329c79d","article-title":"An update on methotrexate","volume":"21","author":"Braun","year":"2009","journal-title":"Curr Opin Rheumatol"},{"key":"10.2515\/therapie\/2011002_bb0020","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.jaad.2008.11.906","article-title":"Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference","volume":"60","author":"Kalb","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.2515\/therapie\/2011002_bb0025","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.biopha.2006.09.007","article-title":"The use of low dose methotrexate in rheumatoid arthritis - are we entering a new era of therapeutic drug monitoring and pharmacogenomics?","volume":"60","author":"Stamp","year":"2006","journal-title":"Biomed Pharmacother"},{"key":"10.2515\/therapie\/2011002_bb0030","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2515\/therapie\/2010016","article-title":"Niveau de preuve du Suivi Th\u00e9rapeutique Pharmacologique du m\u00e9thotrexate au d\u00e9cours de son administration \u00e0 haute-dose","volume":"65","author":"Le Guellec","year":"2010","journal-title":"Th\u00e9rapie"},{"key":"10.2515\/therapie\/2011002_bb0035","series-title":"R\u00e9sum\u00e9 des Caract\u00e9ristiques du Produit du m\u00e9thotrexate","year":"2009"},{"key":"10.2515\/therapie\/2011002_bb0040","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jbspin.2006.01.007","article-title":"Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion","volume":"73","author":"Pavy","year":"2006","journal-title":"Joint Bone Spine"},{"key":"10.2515\/therapie\/2011002_bb0045","first-page":"CD000951","article-title":"Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis","author":"Ortiz","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.2515\/therapie\/2011002_bb0050","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrrheum.2010.5","article-title":"Methotrexate-how does it really work?","volume":"6","author":"Chan","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"10.2515\/therapie\/2011002_bb0055","first-page":"168","article-title":"Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis","volume":"65","author":"Tian","year":"2007","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"10.2515\/therapie\/2011002_bb0060","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1002\/art.24034","article-title":"Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis","volume":"58","author":"Dalrymple","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.2515\/therapie\/2011002_bb0065","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/00007691-199604000-00004","article-title":"Total and free methotrexate pharmacokinetics in rheumatoid arthritis patients","volume":"18","author":"Edno","year":"1996","journal-title":"Ther Drug Monit"},{"key":"10.2515\/therapie\/2011002_bb0070","first-page":"745","article-title":"Methotrexate pharmacokinetics in patients with rheumatoid arthritis","volume":"16","author":"Sinnett","year":"1989","journal-title":"J Rheumatol"},{"key":"10.2515\/therapie\/2011002_bb0075","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2125.1993.tb04158.x","article-title":"The pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis","volume":"35","author":"Seideman","year":"1993","journal-title":"Br J Clin Pharmacol"},{"key":"10.2515\/therapie\/2011002_bb0080","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/jps.2600780219","article-title":"Pharmacokinetics of lowdose methotrexate in rheumatoid arthritis patients","volume":"78","author":"Herman","year":"1989","journal-title":"J Pharm Sci"},{"key":"10.2515\/therapie\/2011002_bb0085","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s002280050404","article-title":"Pharmacokinetics of low doses of methotrexate in patients with psoriasis over the early period of treatment","volume":"53","author":"Chl\u00e1dek","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"10.2515\/therapie\/2011002_bb0090","first-page":"267","article-title":"Pharmacokinetics of small doses of methotrexate in patients with psoriasis","volume":"68","author":"Kamel","year":"1988","journal-title":"Acta Derm Venereol"},{"key":"10.2515\/therapie\/2011002_bb0095","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2165\/00003088-199630030-00002","article-title":"Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis","volume":"30","author":"Bannwarth","year":"1996","journal-title":"Clin Pharmacokinet"},{"key":"10.2515\/therapie\/2011002_bb0100","first-page":"129","article-title":"Pharmacokinetics of methotrexate in rheumatoid arthritis: therapeutic implications","volume":"52","author":"Bannwarth","year":"1997","journal-title":"Therapie"},{"key":"10.2515\/therapie\/2011002_bb0105","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1046\/j.1365-2036.1997.00175.x","article-title":"The absorption of low-dose methotrexate in patients with inflammatory bowel disease","volume":"11","author":"Moshkowitz","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"10.2515\/therapie\/2011002_bb0110","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/art.1780350603","article-title":"Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis","volume":"35","author":"Oguey","year":"1992","journal-title":"Arthritis Rheum"},{"key":"10.2515\/therapie\/2011002_bb0115","first-page":"1570","article-title":"Influence of food on the bioavailability of oral methotrexate in children","volume":"22","author":"Dupuis","year":"1995","journal-title":"J Rheumatol"},{"key":"10.2515\/therapie\/2011002_bb0120","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1046\/j.1365-2036.2003.01614.x","article-title":"Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn\u2019s disease","volume":"18","author":"Kurnik","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.2515\/therapie\/2011002_bb0125","first-page":"1047","article-title":"Methotrexate bioavailability after oral and subcutaneous administration in children with juvenile idiopathic arthritis","volume":"27","author":"Tukov\u00e1","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"10.2515\/therapie\/2011002_bb0130","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/art.27434","article-title":"Analysis of intracellular methotrexate polyglutamates in patients with juvenile idiopathic arthritis: effect of route of administration on variability in intracellular methotrexate polyglutamate concentrations","volume":"62","author":"Becker","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.2515\/therapie\/2011002_bb0135","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/rheumatology\/36.1.86","article-title":"Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis","volume":"36","author":"Hamilton","year":"1997","journal-title":"Br J Rheumatol"},{"key":"10.2515\/therapie\/2011002_bb0140","first-page":"645","article-title":"Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis","volume":"31","author":"Hoekstra","year":"2004","journal-title":"J Rheumatol"},{"issue":"12","key":"10.2515\/therapie\/2011002_bb0145","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1093\/rheumatology\/keq216","article-title":"Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis","volume":"49","author":"Dervieux","year":"2010","journal-title":"Rheumatology"},{"key":"10.2515\/therapie\/2011002_bb0150","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.21762","article-title":"Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis","volume":"54","author":"Ranganathan","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.2515\/therapie\/2011002_bb0155","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1093\/rheumatology\/kem147","article-title":"The pharmacogenetics of methotrexate","volume":"46","author":"Hider","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.2515\/therapie\/2011002_bb0160","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1002\/art.20460","article-title":"Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis","volume":"50","author":"Dervieux","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.2515\/therapie\/2011002_bb0165","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/art.21573","article-title":"Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis","volume":"54","author":"Weisman","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.2515\/therapie\/2011002_bb0170","first-page":"313","article-title":"Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis","volume":"16","author":"Furst","year":"1989","journal-title":"J Rheumatol"},{"key":"10.2515\/therapie\/2011002_bb0175","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/rheumatology\/32.8.751","article-title":"Methotrexate-the relationship between dose and clinical effect","volume":"32","author":"Seideman","year":"1993","journal-title":"Br J Rheumatol"},{"key":"10.2515\/therapie\/2011002_bb0180","first-page":"209","article-title":"Methotrexate serum-level determinations during low-dose therapy of rheumatoid and psoriatic arthritis","volume":"9","author":"Leeb","year":"1989","journal-title":"Int J Clin Pharmacol Res"},{"key":"10.2515\/therapie\/2011002_bb0185","first-page":"465","article-title":"Correlation between methotrexate pharmacokinetic parameters, and clinical and biological status in rheumatoid arthritis patients","volume":"13","author":"Bologna","year":"1995","journal-title":"Clin Exp Rheumatol"},{"key":"10.2515\/therapie\/2011002_bb0190","first-page":"1709","article-title":"Patients with rheumatoid arthritis treated with methotrexate (MTX): concentrations of steady-state erythrocyte MTX correlate to plasma concentrations and clinical efficacy","volume":"35","author":"Hornung","year":"2008","journal-title":"J Rheumatol"},{"key":"10.2515\/therapie\/2011002_bb0195","first-page":"844","article-title":"Lack of correlation between pharmacokinetics and efficacy of low dose methotrexate in patients with rheumatoid arthritis","volume":"22","author":"Lafforgue","year":"1995","journal-title":"J Rheumatol"},{"key":"10.2515\/therapie\/2011002_bb0200","doi-asserted-by":"crossref","first-page":"434","DOI":"10.5414\/CPP42434","article-title":"Monitoring methotrexate therapy in patients with rheumatoid arthritis","volume":"42","author":"Wiela-Hojenska","year":"2004","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.2515\/therapie\/2011002_bb0205","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1620\/tjem.215.95","article-title":"Application of fluorescence polarization immunoassay for determination of methotrexate-polyglutamates in rheumatoid arthritis patients","volume":"215","author":"Hayashi","year":"2008","journal-title":"Tohoku J Exp Med"},{"key":"10.2515\/therapie\/2011002_bb0210","first-page":"313","article-title":"Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis","volume":"17","author":"Angelis-Stoforidis","year":"1999","journal-title":"Clin Exp Rheumatol"},{"key":"10.2515\/therapie\/2011002_bb0215","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1136\/ard.2004.033399","article-title":"Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study","volume":"64","author":"Dervieux","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.2515\/therapie\/2011002_bb0220","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1002\/art.22129","article-title":"Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis","volume":"54","author":"Dervieux","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.2515\/therapie\/2011002_bb0225","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1248\/yakushi.129.843","article-title":"Preliminary study to identify the predictive factors for the response to methotrexate therapy in patients with rheumatoid arthritis","volume":"129","author":"Inoue","year":"2009","journal-title":"Yakugaku Zasshi"},{"key":"10.2515\/therapie\/2011002_bb0230","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/art.27201","article-title":"Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy","volume":"62","author":"Stamp","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.2515\/therapie\/2011002_bb0235","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3109\/s10165-007-0582-y","article-title":"Higher maximal serum concentration of methotrexate predicts the incidence of adverse reactions in Japanese rheumatoid arthritis patients","volume":"17","author":"Shoda","year":"2007","journal-title":"Mod Rheumatol"},{"key":"10.2515\/therapie\/2011002_bb0240","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1046\/j.1365-2125.2002.01621.x","article-title":"Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis","volume":"54","author":"Chl\u00e1dek","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.2515\/therapie\/2011002_bb0245","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1468-3083.2007.02264.x","article-title":"A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment","volume":"22","author":"Hroch","year":"2008","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.2515\/therapie\/2011002_bb0250","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1742-7843.2005.pto960318.x","article-title":"Low-dose methotrexate pharmacokinetics and pharmacodynamics in the therapy of severe psoriasis","volume":"96","author":"Chl\u00e1dek","year":"2005","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.2515\/therapie\/2011002_bb0255","first-page":"1573","article-title":"Plasma levels after oral methotrexate in children with juvenile rheumatoid arthritis","volume":"20","author":"Ravelli","year":"1993","journal-title":"J Rheumatol"},{"key":"10.2515\/therapie\/2011002_bb0260","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/030097400750002085","article-title":"Erythrocyte-methotrexate and disease activity in children treated with oral methotrexate for juvenile chronic arthritis","volume":"29","author":"Kristensen","year":"2000","journal-title":"Scand J Rheumatol"},{"key":"10.2515\/therapie\/2011002_bb0265","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/anr.1780320604","article-title":"Toxicity and serum levels of methotrexate in children with juvenile rheumatoid arthritis","volume":"32","author":"Wallace","year":"1989","journal-title":"Arthritis Rheum"},{"key":"10.2515\/therapie\/2011002_bb0270","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/FTD.0b013e31811f39bb","article-title":"Red blood cell methotrexate polyglutamate concentrations in inflammatory bowel disease","volume":"29","author":"Brooks","year":"2007","journal-title":"Ther Drug Monit"},{"key":"10.2515\/therapie\/2011002_bb0275","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1002\/art.24653","article-title":"Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment","volume":"60","author":"Stamp","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.2515\/therapie\/2011002_bb0280","first-page":"1903","article-title":"Total and free methotrexate pharmacokinetics in elderly patients with rheumatoid arthritis. A comparison with young patients","volume":"24","author":"Bressolle","year":"1997","journal-title":"J Rheumatol"},{"key":"10.2515\/therapie\/2011002_bb0285","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/BF00193703","article-title":"Methotrexate in juvenile rheumatoid arthritis. Evidence of age dependent pharmacokinetics","volume":"47","author":"Albertioni","year":"1995","journal-title":"Eur J Clin Pharmacol"},{"key":"10.2515\/therapie\/2011002_bb0290","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1136\/ard.57.2.110","article-title":"Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients","volume":"57","author":"Bressolle","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"10.2515\/therapie\/2011002_bb0295","first-page":"1356","article-title":"Methotrexate kinetics in rheumatoid arthritis: is there an interaction with nonsteroidal antiinflammatory drugs?","volume":"15","author":"Ahern","year":"1994","journal-title":"J Rheumatol"},{"key":"10.2515\/therapie\/2011002_bb0300","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/(SICI)1099-081X(199804)19:3<163::AID-BDD82>3.0.CO;2-L","article-title":"The effects of non-steroidal antiinflammatory drugs on the disposition of methotrexate in patients with rheumatoid arthritis","volume":"19","author":"Iqbal","year":"1998","journal-title":"Biopharm Drug Dispos"},{"key":"10.2515\/therapie\/2011002_bb0305","first-page":"133","article-title":"Methotrexate and non-steroidal antiinflammatory agent combination in rheumatoid arthritis","volume":"52","author":"Bertin","year":"1997","journal-title":"Therapie"},{"key":"10.2515\/therapie\/2011002_bb0310","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1177\/106002809202600219","article-title":"Methotrexate and nonsteroidal antiinflammatory drug interactions","volume":"26","author":"Frenia","year":"1992","journal-title":"Ann Pharmacother"},{"key":"10.2515\/therapie\/2011002_bb0315","first-page":"1469","article-title":"Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis","volume":"17","author":"Dupuis","year":"1990","journal-title":"J Rheumatol"},{"key":"10.2515\/therapie\/2011002_bb0320","first-page":"1008","article-title":"Lack of significant interaction between low dose methotrexate and ibuprofen or flurbiprofen in patients with arthritis","volume":"17","author":"Skeith","year":"1990","journal-title":"J Rheumatol"},{"key":"10.2515\/therapie\/2011002_bb0325","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1365-2125.1994.tb05713.x","article-title":"Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis","volume":"37","author":"Tracy","year":"1994","journal-title":"Br J Clin Pharmacol"},{"key":"10.2515\/therapie\/2011002_bb0330","first-page":"845","article-title":"Lack of pharmacokinetic interaction of meloxicam with methotrexate in patients with rheumatoid arthritis","volume":"24","author":"H\u00fcbner","year":"1997","journal-title":"J Rheumatol"},{"key":"10.2515\/therapie\/2011002_bb0335","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/rheumatology\/34.5.421","article-title":"Total and free methotrexate pharmacokinetics, with and without piroxicam, in rheumatoid arthritis patients","volume":"34","author":"Combe","year":"1995","journal-title":"Br J Rheumatol"},{"key":"10.2515\/therapie\/2011002_bb0340","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/jps.2600790907","article-title":"Effect of aspirin and sulindac on methotrexate clearance","volume":"79","author":"Furst","year":"1990","journal-title":"J Pharm Sci"},{"key":"10.2515\/therapie\/2011002_bb0345","first-page":"2539","article-title":"Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis","volume":"26","author":"Karim","year":"1999","journal-title":"J Rheumatol"},{"key":"10.2515\/therapie\/2011002_bb0350","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/BF00278469","article-title":"The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis","volume":"42","author":"Tracy","year":"1992","journal-title":"Eur J Clin Pharmacol"},{"key":"10.2515\/therapie\/2011002_bb0355","first-page":"2072","article-title":"The effects of nonsteroidal antiinflammatory drugs on methotrexate (MTX) pharmacokinetics: impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5 mg","volume":"22","author":"Kremer","year":"1995","journal-title":"J Rheumatol"},{"key":"10.2515\/therapie\/2011002_bb0360","first-page":"263","article-title":"Is there an interaction between low doses of corticosteroids and methotrexate in patients with rheumatoid arthritis? A pharmacokinetic study in 33 patients","volume":"20","author":"Lafforgue","year":"1993","journal-title":"J Rheumatol"},{"key":"10.2515\/therapie\/2011002_bb0365","first-page":"1170","article-title":"Do steroids influence low dose methotrexate pharmacokinetics?","volume":"21","author":"Koerber","year":"1994","journal-title":"J Rheumatol"},{"key":"10.2515\/therapie\/2011002_bb0370","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/art.1780370609","article-title":"Chloroquine reduces the bioavailability of methotrexate in patients with rheumatoid arthritis. A possible mechanism of reduced hepatotoxicity","volume":"37","author":"Seideman","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.2515\/therapie\/2011002_bb0375","first-page":"2077","article-title":"Combination therapy with methotrexate and hydroxychloroquine for rheumatoid arthritis increases exposure to methotrexate","volume":"29","author":"Carmichael","year":"2002","journal-title":"J Rheumatol"},{"key":"10.2515\/therapie\/2011002_bb0380","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1046\/j.1365-2125.1996.04038.x","article-title":"Combination of methotrexate and sulphasalazine in patients with rheumatoid arthritis: pharmacokinetic analysis and relationship to clinical response","volume":"42","author":"Haagsma","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"10.2515\/therapie\/2011002_bb0385","article-title":"The interaction between methotrexate and probenecid in man [proceedings]","volume":"63","author":"Aherne","year":"1978","journal-title":"Br J Pharmacol"},{"key":"10.2515\/therapie\/2011002_bb0390","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1248\/yakushi.129.1001","article-title":"Erythrocyte methotrexatepolyglutamate assay using fluorescence polarization immunoassay technique: application to the monitoring of patients with rheumatoid arthritis","volume":"129","author":"Inoue","year":"2009","journal-title":"Yakugaku Zasshi"},{"key":"10.2515\/therapie\/2011002_bb0395","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0378-4347(01)00402-9","article-title":"Separation methods for methotrexate, its structural analogues and metabolites","volume":"764","author":"Rubino","year":"2001","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"10.2515\/therapie\/2011002_bb0400","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jchromb.2006.07.026","article-title":"Method for the determination of blood methotrexate by high performance liquid chromatography with online post-column electrochemical oxidation and fluorescence detection","volume":"845","author":"Li","year":"2007","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.2515\/therapie\/2011002_bb0405","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0378-4347(87)80279-7","article-title":"Column liquid chromatography of methotrexate and its metabolites using a post-column photochemical reactor and fluorescence detection","volume":"419","author":"Salamoun","year":"1987","journal-title":"J Chromatogr"},{"key":"10.2515\/therapie\/2011002_bb0410","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/bdd.654","article-title":"An improved high-performance liquid chromatography method for quantification of methotrexate polyglutamates in red blood cells of children with juvenile idiopathic arthritis","volume":"30","author":"HrochM","year":"2009","journal-title":"Biopharm Drug Dispos"},{"key":"10.2515\/therapie\/2011002_bb0415","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1373\/49.10.1632","article-title":"HPLC determination of erythrocyte methotrexate polyglutamates after low-dose methotrexate therapy in patients with rheumatoid arthritis","volume":"49","author":"Dervieux","year":"2003","journal-title":"Clin Chem"},{"key":"10.2515\/therapie\/2011002_bb0420","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1002\/rcm.4300","article-title":"A novel high-performance liquid chromatography\/mass spectrometry method for improved selective and sensitive measurement of methotrexate polyglutamation status in human red blood cells","volume":"23","author":"Van Haandel","year":"2009","journal-title":"Rapid Commun Mass Spectrom"},{"key":"10.2515\/therapie\/2011002_bb0425","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0021-9673(03)00776-3","article-title":"Simultaneous determination of methotrexate and its eight metabolites in human whole blood by capillary zone electrophoresis","volume":"1014","author":"Kuo","year":"2003","journal-title":"J Chromatogr A"},{"key":"10.2515\/therapie\/2011002_bb0430","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF00226329","article-title":"A limited sampling method to estimate methotrexate pharmacokinetics in patients with rheumatoid arthritis using a Bayesian approach and the population data modeling program P-PHARM","volume":"49","author":"Bressolle","year":"1996","journal-title":"Eur J Clin Pharmacol"},{"key":"10.2515\/therapie\/2011002_bb0435","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1097\/00007691-199412000-00005","article-title":"Methotrexate in rheumatoid arthritisa limited sampling strategy for estimation of the area under the plasma concentration versus time curve","volume":"16","author":"Eksborg","year":"1994","journal-title":"Ther Drug Monit"},{"key":"10.2515\/therapie\/2011002_bb0440","first-page":"21","article-title":"M\u00e9thodologie pour l\u2019\u00e9valuation du niveau de preuve du suivi th\u00e9rapeutique pharmacologique","volume":"23","author":"Le Guellec","year":"2009","journal-title":"La Lettre du Pharmacologue"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716307375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716307375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T22:57:54Z","timestamp":1712357874000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595716307375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":88,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S0040595716307375"],"URL":"https:\/\/doi.org\/10.2515\/therapie\/2011002","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}